BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BRM - US1101221083 - Common Stock
46.015 EUR
-0.37 (-0.79%)
BRM gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BRM get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on BRM. BRM also has an excellent dividend rating. With these ratings, BRM could be worth investigating further for value and dividend investing!.
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
BRM had a positive operating cash flow in the past year.
In multiple years BRM reported negative net income over the last 5 years.
In the past 5 years BRM always reported a positive cash flow from operatings.
1.2 Ratios
BRM has a Return On Assets of 6.23%. This is comparable to the rest of the industry: BRM outperforms 55.56% of its industry peers.
Looking at the Return On Equity, with a value of 32.55%, BRM belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
The Return On Invested Capital of BRM (16.42%) is better than 79.63% of its industry peers.
BRM had an Average Return On Invested Capital over the past 3 years of 10.96%. This is below the industry average of 13.79%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(16.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROIC | 16.42% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
The Profit Margin of BRM (12.57%) is comparable to the rest of the industry.
With an excellent Operating Margin value of 33.51%, BRM belongs to the best of the industry, outperforming 85.19% of the companies in the same industry.
In the last couple of years the Operating Margin of BRM has declined.
BRM's Gross Margin of 73.15% is fine compared to the rest of the industry. BRM outperforms 61.11% of its industry peers.
In the last couple of years the Gross Margin of BRM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
The number of shares outstanding for BRM has been reduced compared to 1 year ago.
Compared to 5 years ago, BRM has less shares outstanding
BRM has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.23 indicates that BRM is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of BRM (2.23) is comparable to the rest of the industry.
The Debt to FCF ratio of BRM is 3.20, which is a good value as it means it would take BRM, 3.20 years of fcf income to pay off all of its debts.
BRM has a better Debt to FCF ratio (3.20) than 61.11% of its industry peers.
BRM has a Debt/Equity ratio of 2.41. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BRM (2.41) is worse than 81.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Altman-Z | 2.23 |
ROIC/WACC1.94
WACC8.46%
2.3 Liquidity
BRM has a Current Ratio of 1.27. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BRM (1.27) is worse than 62.96% of its industry peers.
A Quick Ratio of 1.17 indicates that BRM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.17, BRM is in the better half of the industry, outperforming 68.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 460.68%, which is quite impressive.
Measured over the past years, BRM shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
The Revenue has been growing slightly by 1.26% in the past year.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
3.2 Future
The Earnings Per Share is expected to grow by 35.26% on average over the next years. This is a very strong growth
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.97% yearly.
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.26 indicates a reasonable valuation of BRM.
Based on the Price/Earnings ratio, BRM is valued cheaper than 90.74% of the companies in the same industry.
When comparing the Price/Earnings ratio of BRM to the average of the S&P500 Index (26.59), we can say BRM is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.90, the valuation of BRM can be described as reasonable.
Based on the Price/Forward Earnings ratio, BRM is valued cheaper than 88.89% of the companies in the same industry.
BRM is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 8.9 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaper than 90.74% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.22 | ||
| EV/EBITDA | 6.75 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BRM has a very decent profitability rating, which may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y131.22%
EPS Next 3Y73.98%
5. Dividend
5.1 Amount
BRM has a Yearly Dividend Yield of 4.73%, which is a nice return.
Compared to an average industry Dividend Yield of 1.85, BRM pays a better dividend. On top of this BRM pays more dividend than 87.04% of the companies listed in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.73% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
BRM pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
BRM's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
FRA:BRM (12/23/2025, 7:00:00 PM)
46.015
-0.37 (-0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners81.74%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap93.68B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.65
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.73% |
Yearly Dividend2.06
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)0.56%
PT rev (3m)3.21%
EPS NQ rev (1m)-0.63%
EPS NQ rev (3m)3.78%
EPS NY rev (1m)1.22%
EPS NY rev (3m)0.41%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)1.97%
Revenue NY rev (1m)0.53%
Revenue NY rev (3m)1.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.26 | ||
| Fwd PE | 8.9 | ||
| P/S | 2.3 | ||
| P/FCF | 7.22 | ||
| P/OCF | 6.64 | ||
| P/B | 5.95 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.75 |
EPS(TTM)5.57
EY12.1%
EPS(NY)5.17
Fwd EY11.24%
FCF(TTM)6.38
FCFY13.86%
OCF(TTM)6.93
OCFY15.05%
SpS20.02
BVpS7.73
TBVpS-9.86
PEG (NY)0.02
PEG (5Y)N/A
Graham Number31.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| ROCE | 23.41% | ||
| ROIC | 16.42% | ||
| ROICexc | 21.58% | ||
| ROICexgc | 109.99% | ||
| OM | 33.51% | ||
| PM (TTM) | 12.57% | ||
| GM | 73.15% | ||
| FCFM | 31.86% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.41 | ||
| Debt/FCF | 3.2 | ||
| Debt/EBITDA | 2.13 | ||
| Cap/Depr | 26.84% | ||
| Cap/Sales | 2.75% | ||
| Interest Coverage | 7.66 | ||
| Cash Conversion | 79.11% | ||
| Profit Quality | 253.39% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | 2.23 |
F-Score6
WACC8.46%
ROIC/WACC1.94
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y479.55%
EPS Next 2Y131.22%
EPS Next 3Y73.98%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year0.19%
Revenue Next 2Y-4.06%
Revenue Next 3Y-3.05%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year262.1%
EBIT Next 3Y50.55%
EBIT Next 5Y23.19%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%
BRISTOL-MYERS SQUIBB CO / BRM.DE FAQ
What is the fundamental rating for BRM stock?
ChartMill assigns a fundamental rating of 6 / 10 to BRM.DE.
What is the valuation status for BRM stock?
ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (BRM.DE). This can be considered as Undervalued.
How profitable is BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
BRISTOL-MYERS SQUIBB CO (BRM.DE) has a profitability rating of 6 / 10.
How financially healthy is BRISTOL-MYERS SQUIBB CO?
The financial health rating of BRISTOL-MYERS SQUIBB CO (BRM.DE) is 5 / 10.
What is the expected EPS growth for BRISTOL-MYERS SQUIBB CO (BRM.DE) stock?
The Earnings per Share (EPS) of BRISTOL-MYERS SQUIBB CO (BRM.DE) is expected to grow by 479.55% in the next year.